Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) Equity Average (2018 - 2025)

Historic Equity Average for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $227.8 million.

  • Arcturus Therapeutics Holdings' Equity Average fell 1245.79% to $227.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.8 million, marking a year-over-year decrease of 1245.79%. This contributed to the annual value of $259.7 million for FY2024, which is 534.49% down from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Equity Average stood at $227.8 million for Q3 2025, which was down 1245.79% from $232.4 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year Equity Average high stood at $374.6 million for Q1 2021, and its period low was $158.2 million during Q3 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' median Equity Average value was $260.2 million (recorded in 2024), while the average stood at $257.4 million.
  • In the last 5 years, Arcturus Therapeutics Holdings' Equity Average surged by 165143.78% in 2021 and then crashed by 4599.87% in 2022.
  • Arcturus Therapeutics Holdings' Equity Average (Quarter) stood at $243.7 million in 2021, then decreased by 14.64% to $208.0 million in 2022, then soared by 34.28% to $279.3 million in 2023, then fell by 9.98% to $251.4 million in 2024, then dropped by 9.39% to $227.8 million in 2025.
  • Its Equity Average was $227.8 million in Q3 2025, compared to $232.4 million in Q2 2025 and $237.4 million in Q1 2025.